MRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer?

Journal of Medical Radiation Sciences

Volumn 62, Issue 3, 2015, Pages 212-225

  Schenberg, Tess ^a   Mitchell, Gillian ^a,b   Taylor, Donna ^c,d,e   Saunders, Christobel ^c,f  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e Adelaide Terrace   (Australia)

^f ST JOHN OF GOD HOSPITAL   (Australia)

Author keywords

Australia; Breast; Breast neoplasms; Magnetic resonance imaging; Medicare

Indexed keywords

AUSTRALIAN BREAST MRI SCREENING ACCESS PROGRAM; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; FAMILIAL DISEASE; FEMALE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

EID: 84942077074     PISSN: 20513895     EISSN: 20513909     Source Type: Journal    
DOI: 10.1002/jmrs.116     Document Type: Review

References (71)

1. National Breast and Ovarian Cancer Centre. Advice about familial aspects of breast cancer and epithelial ovarian cancer [Internet]. 2010. [updated 2010; December, cited 2015 Jan 20]. Available from http://canceraustralia.gov.au/sites/default/files/publications/nbocc-bog-2010-web-a4-printable_504af02a673fd.pdf.
2. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-37.
3. Kuhl CK, Schrading S, Leutner CC, et al. Surveillance of "high-risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial. Proc Am Soc Clin Oncol 2003;22: abstract 4, page 2.
4. Liberman L. Breast cancer screening with MRI-what are the data for patients at high risk? N Engl J Med 2004; 351: 497-500.
5. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78.
6. Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. Cancer Res 2002; 21: 115-24.
7. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-102.
8. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-25.
9. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: The EVA trial. J Clin Oncol 2010; 28: 1450-7.
10. Gail MH, Mai PL. Comparing breast cancer risk assessment models. J Natl Cancer Inst 2010; 102: 665-8.
11. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: A review of risk assessment models. J Natl Cancer Inst 2010; 102: 680-91.
12. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early onset breast cancer. Cancer 1994; 73: 643-51.
13. Gail MH, Brinton LA, Byar DP, et al. Projecting individulized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-86.
14. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007; 23: 1782-92.
15. Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Island American women. J Natl Cancer Inst 2011; 103: 951-61.
16. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23: 1111-30.
17. Antoniou AC, Pharoah PPD, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004; 91: 1580-90.
18. Ozanne EM, Drohan B, Bosinoff P, et al. Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomark Prev 2013; 22: 146-9.
19. Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol 2014; 32: 2217-23.
20. American Cancer Society American Cancer Society recommendations for early breast cancer detection in women without breast symptoms [Internet] 2014. 2014. Oct 9 [updated 2015 Apr 9; cited 2015 Jan 20]. Available from http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-acs-recs.
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Screening and Diagnosis Version 1.2014. [Internet] 2014 May 30 [updated 2014 Jul 3; cited 2015 Jan 20]. Available from http://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf.
22. Howell SJ, Searle C, Goode V, et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer 2009; 101: 582-8.
23. Ng AK, Garber JE, Diller LR, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol 2013; 31: 2282-8.
24. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast-risk assessment and management options. N Engl J Med 2015; 372: 78-89.
25. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005; 353: 229-37.
26. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 1993; 17: 14-21.
27. Huo CW, Chew GL, Britt KL, et al. Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat 2014; 144: 479-502.
28. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in post-menopausal women: Approaches to estimating and reducing risk. J Natl Cancer Inst 2009; 101: 384-98.
29. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-36.
30. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: Comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92: 1081-7.
31. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159-69.
32. Kerlikowske K, Cook AJ, Buist DS, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010; 28: 3830-7.
33. Bertrand KA, Tamimi RM, Scott CG, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res 2013; 15: R104.
34. Library of Congress. S.370 - Breast Density and Mammography Reporting Act of 2015. [Internet] 2015 Feb 4 [cited 2015 Feb 6]. Available from: https://www.congress.gov/bill/114th-congress/senate-bill/370.
35. Sprague BL, Stout NK, Schechter C, et al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med 2015; 162: 157-66.
36. Holbrook A, Newel MS. Alternative screening for women with dense breasts: Breast-specific gamma imaging (molecular breast imaging). AJR 2015; 204: 252-6.
37. Lee CI, Cevik M, Alagoz O, et al. Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology 2015; 274: 772-80.
38. Lobbes MB, Smidt ML, Houwers J, Tjan-Heijneri VC, Wildberger JE. Contrast enhanced mammography: Techniques, current results, and potential indications. Clin Radiol 2013; 68: 935-44.
39. Cheung YC, Lin YC, Wan YL, et al. Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: Interobserver blind-reading analysis. Eur Radiol 2014; 24: 2394-403.
40. Carton AK, Gavenonis SC, Currivan JA, Conant EF, Schnall MD, Maidment AD. Dual-energy contrast-enhanced digital breast tomosynthesis-a feasibility study. Br J Radiol 2010; 83: 344-50.
41. Phi XA, Houssami N, Obdeijn IM, et al. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age = 50 years: Evidence from an individual patient Data meta-analysis. J Clin Oncol 2015; 33: 349-56.
42. Cott Chubiz JE, Lee JM, Gilmore ME, et al. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 2013; 119: 1266-76.
43. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: A comparative effectiveness analysis. Cancer 2012; 118: 2021-30.
44. Sardanelli F, Bacigalupo L, Carbonaro L, et al. What is the sensitivity of mammography and dynamic MR imaging for DCIS if the whole-breast histopathology is used as a reference standard? Radiologia Medica 2008; 113: 439-51.
45. Kuhl CK. Why do purely intraductal cancers enhance on breast MR images? Radiology 2009; 253: 281-3.
46. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356: 1295-303.
47. Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 2007; 370: 485-92.
48. Esserman LJ, Kumar AS, Herrera AF, et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 2006; 24: 4603-10.
49. Jansen SA, Newstead GM, Abe H, et al. Pure ductal carcinoma in situ: Kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. Radiology 2007; 245: 684-91.
50. Reidl CC, Luft N, Bernhart C, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 2015; 33: 1128-35.
51. Evans DG, Kesavan N, Lim Y, et al. MRI breast screening in high-risk women: Cancer detection and survival analysis. Breast Cancer Res Treat 2014; 145: 663-72.
52. Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, et al. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst 2013; 105: 1314-21.
53. Chiarelli AM, Prummel MV, Muradali D, et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: Results of the initial screen from the Ontario high risk breast screening program. J Clin Oncol 2014; 32: 2224-30.
54. Rjinsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: Long-term follow-up of the dutch MRISC screening study. J Clin Oncol 2010; 28: 5265-72.
55. Kuhl C, Schrading S, Leutner C, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-76.
56. Hagen AI, Kvistad KA, Maehle L, et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007; 16: 367-74.
57. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29: 1664-9.
58. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012; 107: 24-30.
59. Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007; 43: 1905-17.
60. Australian Institute of Health and Welfare Breast Screen Australia monitoring report 2011-2012. Cancer series no.86. 2014. Cat. no.CAN 83. Canberra: AIHW.
61. Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006; 295: 2374-84.
62. Griebsch I, Brown J, Boggis C, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 2006; 95: 801-10.
63. Lee JM, McMahon PM, Kong CY, et al. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology 2010; 254: 793-800.
64. Ahern CH, Shih YT, Dong W, Parmigiani G, Shen Y. Cost-effectiveness of alternative strategies for intergrating MRI into breast cancer screening for women at high risk. Br J Cancer 2014; 111: 1542-51.
65. Kiely BE, Hossack LK, Shadbolt CL, et al. Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer. ANZ J Surg 2011; 81: 688-93.
66. Stout NK, Nekhlyudov L, Li L, et al. Rapid increase in breast magnetic resonance imaging use: Trends from 2000 to 2011. JAMA Intern Med 2014; 174: 114-21.
67. Brett J, Austoker J. Women who are recalled for further investigation for breast screening: Psychological consequences 3 years after recall and factors affecting re-attendance. J Public Health Med 2001; 23: 292-300.
68. Brewer NT, Salz T, Lillie SE. Systematic review: The long-term effects of false-positive mammograms. Ann Intern Med 2007; 146: 502-10.
69. Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 2013; 11: 106-15.
70. Australian Health Ministers' Advisory Council. Population Based Screening Framework. Commonwealth of Australia, Canberra, 2008; pp. 24.
71. National Institute for Health and Care Excellence Familial Breast Cancer Guidelines. [Internet] 2013 June [cited 2015 Jan 20]. Available from: http://www.nice.org.uk/guidance/cg164/resources/guidance-familial-breast-cancer-pdf.